• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定和评价具有生物活性的天然产物作为人类微管亲和调节激酶 4(MARK4)潜在抑制剂的研究。

Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).

机构信息

a Centre for Interdisciplinary Research in Basic Sciences , Jamia Millia Islamia , Jamia Nagar, New Delhi , 110025 , India.

b Computational Mechanistic Chemistry and Drug Discovery , Rhodes University , Grahamstown , South Africa.

出版信息

J Biomol Struct Dyn. 2019 Apr;37(7):1813-1829. doi: 10.1080/07391102.2018.1468282. Epub 2018 May 24.

DOI:10.1080/07391102.2018.1468282
PMID:29683402
Abstract

Microtubule affinity-regulating kinase 4 (MARK4) has recently been identified as a potential drug target for several complex diseases including cancer, diabetes and neurodegenerative disorders. Inhibition of MARK4 activity is an appealing therapeutic option to treat such diseases. Here, we have performed structure-based virtual high-throughput screening of 100,000 naturally occurring compounds from ZINC database against MARK4 to find its potential inhibitors. The resulted hits were selected, based on the binding affinities, docking scores and selectivity. Further, binding energy calculation, Lipinski filtration and ADMET prediction were carried out to find safe and better hits against MARK4. Best 10 compounds bearing high specificity and binding efficiency were selected, and their binding pattern to MARK4 was analyzed in detail. Finally, 100 ns molecular dynamics simulation was performed to evaluate; the dynamics stability of MARK4-compound complex. In conclusion, these selected natural compounds from ZINC database might be potential leads against MARK4, and can further be exploited in drug design and development for associated diseases.

摘要

微管亲和调节激酶 4(MARK4)最近被确定为几种复杂疾病(包括癌症、糖尿病和神经退行性疾病)的潜在药物靶点。抑制 MARK4 的活性是治疗此类疾病的一种有吸引力的治疗选择。在这里,我们针对 MARK4 对 ZINC 数据库中的 100,000 种天然化合物进行了基于结构的虚拟高通量筛选,以寻找其潜在的抑制剂。根据结合亲和力、对接评分和选择性选择命中结果。此外,进行结合能计算、Lipinski 过滤和 ADMET 预测,以找到针对 MARK4 的安全且更好的命中结果。选择了 10 个具有高特异性和结合效率的最佳化合物,并详细分析了它们与 MARK4 的结合模式。最后,进行了 100ns 分子动力学模拟,以评估 MARK4-化合物复合物的动力学稳定性。总之,这些来自 ZINC 数据库的天然化合物可能是针对 MARK4 的潜在先导化合物,并可进一步用于相关疾病的药物设计和开发。

相似文献

1
Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).鉴定和评价具有生物活性的天然产物作为人类微管亲和调节激酶 4(MARK4)潜在抑制剂的研究。
J Biomol Struct Dyn. 2019 Apr;37(7):1813-1829. doi: 10.1080/07391102.2018.1468282. Epub 2018 May 24.
2
Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.设计新型激酶抑制剂衍生物作为常见复杂疾病的治疗药物:微管亲和力调节激酶4(MARK4)抑制的结构基础
OMICS. 2015 Nov;19(11):700-11. doi: 10.1089/omi.2015.0111.
3
Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.人微管亲和调节激酶 4 抑制剂的评价:荧光结合研究、酶和细胞测定。
J Biomol Struct Dyn. 2017 Nov;35(14):3194-3203. doi: 10.1080/07391102.2016.1249958. Epub 2016 Nov 3.
4
PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4.PKR抑制剂与人微管亲和力调节激酶4有效结合。
J Mol Graph Model. 2015 Nov;62:245-252. doi: 10.1016/j.jmgm.2015.10.009. Epub 2015 Oct 21.
5
Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.基于结构的柚皮素对 MARK4 抑制潜力的研究及其在癌症和神经退行性疾病治疗中的应用。
J Cell Biochem. 2021 Oct;122(10):1445-1459. doi: 10.1002/jcb.30022. Epub 2021 Jun 14.
6
Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.针对阿尔茨海默病的环依赖性激酶 5 进行小分子天然产物的虚拟筛选、药代动力学、分子动力学和结合自由能分析。
J Biomol Struct Dyn. 2020 Jan;38(1):248-262. doi: 10.1080/07391102.2019.1571947. Epub 2019 Feb 21.
7
Virtual Screening Approach to Identify High-Affinity Inhibitors of Serum and Glucocorticoid-Regulated Kinase 1 among Bioactive Natural Products: Combined Molecular Docking and Simulation Studies.虚拟筛选方法鉴定生物活性天然产物中高亲和力的血清和糖皮质激素调节激酶 1 抑制剂:联合分子对接和模拟研究。
Molecules. 2020 Feb 13;25(4):823. doi: 10.3390/molecules25040823.
8
Identification of mitogen-activated protein kinase 7 inhibitors from natural products: Combined virtual screening and dynamic simulation studies.从天然产物中鉴定丝裂原活化蛋白激酶 7 抑制剂:虚拟筛选和动态模拟研究的结合。
J Mol Recognit. 2024 Jan;37(1):e3067. doi: 10.1002/jmr.3067. Epub 2023 Nov 13.
9
MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease.鸢尾素抑制丝氨酸/苏氨酸蛋白激酶 MAP/Microtubule Affinity Regulating Kinase 4 的潜力:一种对抗癌症和阿尔茨海默病的新治疗策略。
Int J Mol Sci. 2021 Oct 12;22(20):10986. doi: 10.3390/ijms222010986.
10
Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: Towards therapeutic implications in neurodegenerative diseases.胆酸抑制 MARK4 活性的结构和生化研究:在神经退行性疾病治疗中的潜在应用。
Int J Biol Macromol. 2020 Oct 15;161:596-604. doi: 10.1016/j.ijbiomac.2020.06.078. Epub 2020 Jun 11.

引用本文的文献

1
Exploring anticancer activity of baicalin, naringenin, and noscapine via binding and inhibition of sphingosine kinase 1.通过结合和抑制鞘氨醇激酶1探索黄芩苷、柚皮素和那可丁的抗癌活性。
3 Biotech. 2025 Jun;15(6):195. doi: 10.1007/s13205-025-04356-9. Epub 2025 May 29.
2
Structure-guided screening identified bioactive phytoconstituents Hernandonine and Anolobine as potential inhibitors of dual specificity protein kinase CLK1.基于结构的筛选确定了生物活性植物成分 Hernandonine 和 Anolobine 作为双特异性蛋白激酶 CLK1 的潜在抑制剂。
Sci Rep. 2025 Apr 19;15(1):13604. doi: 10.1038/s41598-025-97753-2.
3
Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics.
基于结构导向鉴定用于抗癌治疗的丝裂原活化蛋白激酶-1抑制剂。
PLoS One. 2025 Jan 24;20(1):e0311954. doi: 10.1371/journal.pone.0311954. eCollection 2025.
4
Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.癌症治疗中的前沿融合:纳米材料、间充质干细胞和微生物制剂的作用——挑战与局限
Discov Oncol. 2024 Dec 21;15(1):818. doi: 10.1007/s12672-024-01590-0.
5
Vanillin-Isatin Hybrid-Induced MARK4 Inhibition As a Promising Therapeutic Strategy against Hepatocellular Carcinoma.香草醛-异吲哚酮杂合物诱导的MARK4抑制作为一种有前景的肝细胞癌治疗策略
ACS Omega. 2024 Jun 5;9(24):25945-25959. doi: 10.1021/acsomega.4c00661. eCollection 2024 Jun 18.
6
Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer's disease.加兰他敏对MARK4的抑制作用机制洞察及其对阿尔茨海默病治疗靶点的影响
Front Pharmacol. 2023 Sep 19;14:1276179. doi: 10.3389/fphar.2023.1276179. eCollection 2023.
7
Identifying β-secretase 1 (BACE1) inhibitors from plant-based compounds: an approach targeting Alzheimer's therapeutics employing molecular docking and dynamics simulation.从植物性化合物中鉴定β-分泌酶1(BACE1)抑制剂:一种采用分子对接和动力学模拟靶向阿尔茨海默病治疗的方法。
Mol Divers. 2024 Oct;28(5):2967-2980. doi: 10.1007/s11030-023-10726-3. Epub 2023 Sep 20.
8
Targeting Filamenting temperature-sensitive mutant Z (FtsZ) with bioactive phytoconstituents: An emerging strategy for antibacterial therapy.利用具有生物活性的植物化合物靶向丝状温度敏感突变 Z(FtsZ):一种新兴的抗菌治疗策略。
PLoS One. 2023 Aug 30;18(8):e0290852. doi: 10.1371/journal.pone.0290852. eCollection 2023.
9
Rational Design of Daunorubicin C-14 Hydroxylase Based on the Understanding of Its Substrate-Binding Mechanism.基于对其底物结合机制的理解,对柔红霉素 C-14 羟化酶进行合理设计。
Int J Mol Sci. 2023 May 6;24(9):8337. doi: 10.3390/ijms24098337.
10
Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.结构导向方法发现结核菌素作为丙酮酸激酶 M2 的有效激活剂,靶向癌症治疗。
Int J Mol Sci. 2022 Oct 29;23(21):13172. doi: 10.3390/ijms232113172.